Aptorum's Shares Jump After ALS-4 Targeting Staphylococcus Aureus Shows Encouraging Action In Early-Stage Study

Aptorum Group Limited APM has completed two initial cohorts of the single-dose ascending dose (SAD) portion of the Phase 1 trial evaluating ALS-4 small molecule targeting Staphylococcus aureus.
Total 6 cohorts for SAD and three cohorts for multiple ascending doses (MAD) have been planned.
Dosing and safety reviews of Cohort A (25mg) and Cohort B (50mg) have been completed. No human subjects were dropped out of the studies, and there were no Serious Adverse Events observed.
In addition, no relevant clinical changes regarding vital signs, ECG, clinical laboratory test results, and physical examinations were observed compared to the relevant baseline.
Cohort C (100mg) studies have been initiated.
The company also completed the Pre-IND meeting with the FDA related to SACT-1, a repurposed small molecule targeting neuroblastoma.
SACT-1 is on track to start clinical studies in Q3 of 2021.
Price Action: APM shares are up 32.4% at $3.15 on the last check Monday.